From the Department of Nuclear Medicine, Rabin Medical Center, Petah Tikva.
Department of Nuclear Medicine, Bnai Zion Medical Center and Faculty of Medicine, The Technion-Israel Institute of Technology, Haifa, Israel.
Clin Nucl Med. 2021 May 1;46(5):396-401. doi: 10.1097/RLU.0000000000003648.
Recognition of the pattern of FDG uptake in hypermetabolic axillary lymph nodes (HALs) and association with recent messenger RNA (mRNA) vaccination are important to prevent patient anxiety and further needless examinations or costly biopsies in cancer patients.
This study was a retrospective cohort study in a single tertiary care institution. We investigate the occurrence and pattern of HAL on FDG PET/CT scans from 650 consecutive cancer patients with recent BNT162b2 mRNA COVID-19 vaccination.
Between December 20, 2020, and February 8, 2021, 650 patients (351 female patients [54%]; mean age, 68.9 years) had recent mRNA COVID-19 vaccination and an FDG PET/CT scan. HALs were found in 57 (14.5%) of 394 patients (95% confidence interval [CI], 10.9%-18.7%) 12.3 ± 5.9 (1-22) days after dose 1 and in 111 (43.3%) of 256 patients (95% CI, 35.3%-52.2%; P < 0.0001) after 7.5 ± 5.4 (1-22) days after dose 2. There was no difference between dose 1 and dose 2 concerning SUVmax (3.7 ± 1.8 [1.3-11.3] and 4.5 ± 3.9 [1.4-26.3], P = 0.13, respectively), SUVmean (2.1 ± 1.0 [0.7-6.5] and 2.7 ± 2.4 [0.8-17], P = 0.08, respectively), and reactogenicity volume (2.7 ± 2.3 [0.2-11.6] cm3 and 2.7 ± 2.4 [0.2-15.5] cm3, P = 0.98, respectively). There was no difference in number and in size of positive lymph nodes between dose 1 and dose 2: 3.2 ± 2.2 (1-10) and 3.7 ± 2.4 (1-12) (P = 0.18), and 1.4 ± 0.4 cm (0.7-2.5 cm) and 1.5 ± 0.4 cm (0.6-3.2 cm) (P = 0.75), respectively.
A cluster pattern of hypermetabolic ipsilateral small axillary lymph nodes is common after mRNA COVID-19 vaccination, mainly after the second injection.
识别 FDG 摄取在高代谢腋窝淋巴结(HALs)中的模式,并与近期信使 RNA(mRNA)疫苗接种相关联,这对于预防癌症患者的焦虑以及进一步进行不必要的检查或昂贵的活检非常重要。
这是在一家单一的三级医疗机构进行的回顾性队列研究。我们调查了 650 例最近接受 BNT162b2 mRNA COVID-19 疫苗接种的连续癌症患者的 FDG PET/CT 扫描中 HAL 的发生和模式。
在 2020 年 12 月 20 日至 2021 年 2 月 8 日期间,650 例患者(351 例女性患者[54%];平均年龄 68.9 岁)最近接受了 mRNA COVID-19 疫苗接种和 FDG PET/CT 扫描。在第 1 剂后 12.3 ± 5.9(1-22)天,在第 394 例患者(95%置信区间[CI],10.9%-18.7%)中发现了 57 例(14.5%)HAL,在第 2 剂后 7.5 ± 5.4(1-22)天,在第 256 例患者(95%CI,35.3%-52.2%;P < 0.0001)中发现了 111 例(43.3%)HAL。在第 1 剂和第 2 剂之间,SUVmax(分别为 3.7 ± 1.8[1.3-11.3]和 4.5 ± 3.9[1.4-26.3])、SUVmean(分别为 2.1 ± 1.0[0.7-6.5]和 2.7 ± 2.4[0.8-17])和反应性体积(分别为 2.7 ± 2.3[0.2-11.6]cm3和 2.7 ± 2.4[0.2-15.5]cm3)之间无差异(P 分别为 0.13、0.08 和 0.98)。在第 1 剂和第 2 剂之间,阳性淋巴结的数量和大小无差异:3.2 ± 2.2(1-10)和 3.7 ± 2.4(1-12)(P = 0.18),1.4 ± 0.4 cm(0.7-2.5 cm)和 1.5 ± 0.4 cm(0.6-3.2 cm)(P = 0.75)。
在接受 mRNA COVID-19 疫苗接种后,同侧小腋窝淋巴结出现高代谢簇状模式很常见,主要发生在第二次注射后。